Abstract
In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA coronavirus disease 2019 (COVID-19) vaccine-associated myopericarditis was noted. Only one adolescent with life-threatening complications was reported, with no deaths at any of the participating institutions.
Original language | English |
---|---|
Pages (from-to) | 208-213.e3 |
Journal | Journal of Pediatrics |
Volume | 243 |
DOIs | |
State | Published - Apr 2022 |
Keywords
- mRNA COVID-19 vaccine-associated myopericarditis
- outcomes
- survey
- variability